CN101810563B - Tacrolimus ophthalmic in-situ gel preparation and preparation method thereof - Google Patents
Tacrolimus ophthalmic in-situ gel preparation and preparation method thereof Download PDFInfo
- Publication number
- CN101810563B CN101810563B CN2009103077536A CN200910307753A CN101810563B CN 101810563 B CN101810563 B CN 101810563B CN 2009103077536 A CN2009103077536 A CN 2009103077536A CN 200910307753 A CN200910307753 A CN 200910307753A CN 101810563 B CN101810563 B CN 101810563B
- Authority
- CN
- China
- Prior art keywords
- tacrolimus
- gel
- type
- preparation
- responsive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 title claims description 256
- 229960001967 tacrolimus Drugs 0.000 title claims description 255
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 title claims description 251
- 238000002360 preparation method Methods 0.000 title claims description 138
- 238000011065 in-situ storage Methods 0.000 title description 2
- 239000000203 mixture Substances 0.000 claims description 118
- 238000003756 stirring Methods 0.000 claims description 115
- 239000003795 chemical substances by application Substances 0.000 claims description 102
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 87
- 238000000034 method Methods 0.000 claims description 83
- 239000000243 solution Substances 0.000 claims description 71
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 67
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 66
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 66
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 64
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 60
- 230000002421 anti-septic effect Effects 0.000 claims description 60
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 60
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 49
- 150000002500 ions Chemical class 0.000 claims description 46
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 46
- 239000007924 injection Substances 0.000 claims description 44
- 238000002347 injection Methods 0.000 claims description 44
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 41
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 40
- 229920000858 Cyclodextrin Polymers 0.000 claims description 40
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 claims description 40
- 238000005352 clarification Methods 0.000 claims description 37
- 238000005303 weighing Methods 0.000 claims description 37
- -1 carboxymethyl cyclodextrin Chemical compound 0.000 claims description 36
- 230000008569 process Effects 0.000 claims description 30
- 239000003814 drug Substances 0.000 claims description 29
- 239000011780 sodium chloride Substances 0.000 claims description 28
- 239000004744 fabric Substances 0.000 claims description 27
- 230000003020 moisturizing effect Effects 0.000 claims description 27
- 238000012856 packing Methods 0.000 claims description 27
- 230000001954 sterilising effect Effects 0.000 claims description 27
- 239000008187 granular material Substances 0.000 claims description 25
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 25
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical group C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 24
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 24
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 24
- 239000012876 carrier material Substances 0.000 claims description 24
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 23
- 239000008103 glucose Substances 0.000 claims description 23
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 23
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 23
- 229960003415 propylparaben Drugs 0.000 claims description 23
- 229960002233 benzalkonium bromide Drugs 0.000 claims description 22
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 claims description 22
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 21
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 21
- 239000002994 raw material Substances 0.000 claims description 21
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 20
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 20
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 20
- 229930195725 Mannitol Natural products 0.000 claims description 20
- 229960000583 acetic acid Drugs 0.000 claims description 20
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 20
- 239000004327 boric acid Substances 0.000 claims description 20
- 229960004926 chlorobutanol Drugs 0.000 claims description 20
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 20
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 20
- 239000012362 glacial acetic acid Substances 0.000 claims description 20
- 239000000594 mannitol Substances 0.000 claims description 20
- 235000010355 mannitol Nutrition 0.000 claims description 20
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 claims description 20
- 239000008363 phosphate buffer Substances 0.000 claims description 20
- 239000001509 sodium citrate Substances 0.000 claims description 20
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 20
- 239000000600 sorbitol Substances 0.000 claims description 20
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 claims description 20
- 229940033663 thimerosal Drugs 0.000 claims description 20
- GSEJCLTVZPLZKY-UHFFFAOYSA-O triethanolammonium Chemical compound OCC[NH+](CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-O 0.000 claims description 20
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 18
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 18
- 239000002904 solvent Substances 0.000 claims description 17
- 241001597008 Nomeidae Species 0.000 claims description 16
- 238000004108 freeze drying Methods 0.000 claims description 15
- 229920001983 poloxamer Polymers 0.000 claims description 15
- 229960000502 poloxamer Drugs 0.000 claims description 15
- 229920000609 methyl cellulose Polymers 0.000 claims description 14
- 239000001923 methylcellulose Substances 0.000 claims description 14
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 14
- 229920001223 polyethylene glycol Polymers 0.000 claims description 14
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 13
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 13
- 229920000896 Ethulose Polymers 0.000 claims description 12
- 239000001859 Ethyl hydroxyethyl cellulose Substances 0.000 claims description 12
- 239000004698 Polyethylene Substances 0.000 claims description 12
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 12
- 229920002125 Sokalan® Polymers 0.000 claims description 12
- 229920001400 block copolymer Polymers 0.000 claims description 12
- 229960001631 carbomer Drugs 0.000 claims description 12
- 235000019326 ethyl hydroxyethyl cellulose Nutrition 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 12
- 239000004310 lactic acid Substances 0.000 claims description 12
- QNILTEGFHQSKFF-UHFFFAOYSA-N n-propan-2-ylprop-2-enamide Chemical class CC(C)NC(=O)C=C QNILTEGFHQSKFF-UHFFFAOYSA-N 0.000 claims description 12
- 229920000573 polyethylene Polymers 0.000 claims description 12
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 12
- 239000002671 adjuvant Substances 0.000 claims description 11
- 229920002148 Gellan gum Polymers 0.000 claims description 10
- 150000002148 esters Chemical class 0.000 claims description 10
- 239000000216 gellan gum Substances 0.000 claims description 10
- 235000010492 gellan gum Nutrition 0.000 claims description 10
- 230000010355 oscillation Effects 0.000 claims description 10
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 8
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 8
- 229920001661 Chitosan Polymers 0.000 claims description 8
- 229940072056 alginate Drugs 0.000 claims description 8
- 235000010443 alginic acid Nutrition 0.000 claims description 8
- 229920000615 alginic acid Polymers 0.000 claims description 8
- 150000004676 glycans Chemical class 0.000 claims description 8
- 229920001282 polysaccharide Polymers 0.000 claims description 8
- 239000005017 polysaccharide Substances 0.000 claims description 8
- 229940100655 ophthalmic gel Drugs 0.000 claims description 5
- 239000001116 FEMA 4028 Substances 0.000 claims description 2
- 229960004853 betadex Drugs 0.000 claims description 2
- 239000007962 solid dispersion Substances 0.000 description 21
- 229940079593 drug Drugs 0.000 description 20
- 239000003889 eye drop Substances 0.000 description 20
- 210000004087 cornea Anatomy 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 239000000843 powder Substances 0.000 description 14
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 12
- 230000002980 postoperative effect Effects 0.000 description 11
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 10
- 241000196324 Embryophyta Species 0.000 description 10
- 241000283973 Oryctolagus cuniculus Species 0.000 description 10
- 238000007500 overflow downdraw method Methods 0.000 description 10
- 238000002054 transplantation Methods 0.000 description 9
- 230000004927 fusion Effects 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 239000007788 liquid Substances 0.000 description 7
- 108010036949 Cyclosporine Proteins 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 6
- 229960001265 ciclosporin Drugs 0.000 description 6
- 229940044476 poloxamer 407 Drugs 0.000 description 6
- 229920001992 poloxamer 407 Polymers 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 230000001900 immune effect Effects 0.000 description 5
- 230000007928 solubilization Effects 0.000 description 5
- 238000005063 solubilization Methods 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 229930105110 Cyclosporin A Natural products 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 206010052779 Transplant rejections Diseases 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000036760 body temperature Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 239000002195 soluble material Substances 0.000 description 4
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 3
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 206010002198 Anaphylactic reaction Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000036783 anaphylactic response Effects 0.000 description 3
- 208000003455 anaphylaxis Diseases 0.000 description 3
- 230000007797 corrosion Effects 0.000 description 3
- 238000005260 corrosion Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 229960003376 levofloxacin Drugs 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 229940044519 poloxamer 188 Drugs 0.000 description 3
- 229920001993 poloxamer 188 Polymers 0.000 description 3
- 239000000661 sodium alginate Substances 0.000 description 3
- 235000010413 sodium alginate Nutrition 0.000 description 3
- 229940005550 sodium alginate Drugs 0.000 description 3
- 230000007480 spreading Effects 0.000 description 3
- 238000003892 spreading Methods 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 238000001291 vacuum drying Methods 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000031354 Hyphema Diseases 0.000 description 2
- 241000150100 Margo Species 0.000 description 2
- 206010029350 Neurotoxicity Diseases 0.000 description 2
- 206010044221 Toxic encephalopathy Diseases 0.000 description 2
- 206010048222 Xerosis Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000002159 anterior chamber Anatomy 0.000 description 2
- 210000000795 conjunctiva Anatomy 0.000 description 2
- 231100000478 corneal permeability Toxicity 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 206010023365 keratopathy Diseases 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 231100000228 neurotoxicity Toxicity 0.000 description 2
- 230000007135 neurotoxicity Effects 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 2
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000009786 Anophthalmos Diseases 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 102000004631 Calcineurin Human genes 0.000 description 1
- 108010042955 Calcineurin Proteins 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010015946 Eye irritation Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 206010053675 Iris incarceration Diseases 0.000 description 1
- 241000347881 Kadua laxiflora Species 0.000 description 1
- 206010024214 Lenticular opacities Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 108010006877 Tacrolimus Binding Protein 1A Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 241000425571 Trepanes Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 1
- HOBWAPHTEJGALG-JKCMADFCSA-N [(1r,5s)-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;sulfate Chemical compound [O-]S([O-])(=O)=O.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1 HOBWAPHTEJGALG-JKCMADFCSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960002028 atropine sulfate Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960002344 dexamethasone sodium phosphate Drugs 0.000 description 1
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 125000005594 diketone group Chemical group 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 231100000013 eye irritation Toxicity 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- RNAICSBVACLLGM-GNAZCLTHSA-N pilocarpine hydrochloride Chemical compound Cl.C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C RNAICSBVACLLGM-GNAZCLTHSA-N 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229960004791 tropicamide Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a tacrolimus ophthalmic in-situ gel preparation and a preparation method thereof, which micronizes medicaments or adopts the solid dispersion technology, the cyclodextrin inclusion technology or the like to obviously improve the solubility and then to prepare into an ophthalmic preparation which is in the liquid state in vitro and is in the gel state when being dropped into eyes. The invention is applicable to the treatment for preventing and curing ophthalmic corneal transplantation rejection, keratoconjunctivitis (KC), ocular allergic disorders and the like. The invention prepares tacrolimus into the ophthalmic in-situ gel for the first time. The ophthalmic gel is in the liquid state in vitro, the dosage can be easily and accurately controlled, the operation is convenient, and the ophthalmic gel can be uniformly spread when being dropped into eyes to form the gel. The ophthalmic gel can stay in eyes for long, can not be easily diluted by tears, can maintain the concentration of the effective medicaments, enhances the treatment effect, and has the advantages of less stimulation and good biocompatibility, thereby being an effective new ophthalmic medicine, being applicable to the clinic treatment and having extensive development prospect.
Description
Technical field
The invention belongs to drug world, more specifically relate to a kind of tacrolimus ophthalmic and be used in body gel preparation and preparation method thereof.
Background technology
The keratopathy that a variety of causes causes is present domestic topmost blinding keratopathy, and annual number of patients reaches more than 1,000,000, and corneal graft is the main method of this type of disease of treatment, and the immunological rejection behind the corneal graft is present a great problem.Glucocorticoid is the main means of control postoperative graft-rejection, but its prolonged application not only can cause multiple complications, and often can not suppress the rejection of high-risk corneal transplantation postoperative effectively.In recent years ciclosporin A in the application of ophthalmology more and more widely, but ciclosporin eye drop solvent is an oiliness, it splashes into the eye back has very strong zest to eyes, the patient can not tolerate usually, and has allergic phenomena to take place.Clinical trial shows that the application of tacrolimus in transplanting such as the heart, lung, intestinal, bone marrow has better curative effect.It is treating LADA oculopathy, eye anaphylaxis illness simultaneously, and the immunological rejection after the corneal transplantation all has good curative effect.Its mechanism of action is similar with Ciclosporin A (CsA), and immunosuppressive activity is strong 100 times than Ciclosporin A, and the toxicity incidence rate is lower.
Tacrolimus (Tacrolimus, FK506) be Japanese scholar in 1984 building the novel immunosuppressant of from soil fungi, extracting in the rolling land district of a kind of Macrolide, by one and half ketone groups, α, β diketone base and 23 rings are formed, its molecular formula is C
44H
69NO
12H
2O, molecular weight are 822.5.Be white in color under the room temperature crystallization or crystalline powder, water insoluble, dissolubility 1～2 μ gml in the water
-1, be dissolved in methanol, ethanol, acetone, chloroform, ethyl acetate, slightly be dissolved in hexane, petroleum ether.Be the lipophilic hydrophobicity, its fusing point is 127～129 ℃.
Its chemical constitution such as Fig. 1.
Its mechanism of action is to suppress lymphocyte activation through the activity that suppresses the relevant cell factor transcription factor.Tacrolimus is combined into FK506-FKBP12 with receptor protein FKBP12 earlier after getting into cell, and this complex combines and suppress its activity again with the calcineurin high-affinity, finally suppress transcribing of IL-2, blocking-up Ca
2+The activated channel of dependent cell, cell thereby be suppressed, thus bring into play powerful immunosuppressive action.
At present, the preparation that gone on the market is mainly oral formulations and injection, is Japanese import.But its whole body administration common adverse reactions have tremble, headache, infection, paraesthesia, neurotoxicity and renal function go down.Idol has that diarrhoea, serum creatinine increase, insomnia, blood glucose are increased, chest pain and other untoward reaction such as feel sick.Tacrolimus is prepared into ophthalmic preparation, has the characteristics of safety, efficient, no whole body toxic and side effects, and at present still anophthalmia go on the market with preparation.But this drug main will have problems as follows: tacrolimus is water insoluble, and the ophthalmic permeability is poor, is difficult to reach within the eye treatment level, makes its bioavailability lower, and how increasing its dissolubility is a major issue that must solve.Cyclodextrin inclusion technique can increase the dissolubility of insoluble drug, and eyes are not had zest, can promote the corneal permeability of medicine in the time of solubilising, is suitable as very much the adjuvant of preparation ophthalmic preparation.Meanwhile, cyclodextrin inclusion technique has certain effect to the curative effect of medication that improves poorly water-soluble.Because these medicines dissolubility in clathrate increases, thereby dosage can increase, and when clathrate contact with cornea, because free drug constantly release from dynamic equilibrium, absorption rate is slack-off, and the free drug that contacts with absorption site in the part increases.Add the eye irritation that cyclodextrin also can alleviate some drugs in the eye drop.This problem is chosen cyclodextrin inclusion technique and is prepared the tacrolimus cyclodextrin clathrate as intermediate, to increase dissolubility and the corneal permeability of tacrolimus in water, improves bioavailability, and then is prepared into eye and is used in the body gel.This gel for eye use external be liquid condition, splashing into behind the ophthalmic can uniform spreading, and forms gel.The solution gel property of transition of this uniqueness makes it have that preparation is simple, divided dose is accurate, easy to use, particularly the mucosal tissue affinity is strong, the holdup time is long with agents area, zest is little, advantages such as good biocompatibility.In addition, can more help the treatment of corneal allograft rejection and other immune associated ophthalmopathies guaranteeing to reduce dosage, minimizing systemic absorption and toxic and side effects under the pharmaceutically-active prerequisite.
Summary of the invention
The purpose of this invention is to provide a kind of tacrolimus ophthalmic and be used in body gel preparation and preparation method thereof, solve that tacrolimus is that oral formulations and injection bring problems such as the big toxic and side effects of human body in the prior art, the dissolubility of physical ability increase medicine in the middle of the tacrolimus wherein, this gel for eye use external be liquid condition; Dosage is control easily accurately, and is easy to use, and splashing into behind the ophthalmic can uniform spreading, and forms gel; Within the eye the time of staying longer, be difficult for being kept active drug concentration by the tear dilution; Enhancing treatment effect, and zest is little, good biocompatibility; Be that a kind of effective eye is used new drug, can be applied to clinically to have the wide development prospect.
The tacrolimus ophthalmic that the present invention is used for treatments such as ophthalmic cornea graft-rejection, eye cornea and conjunctiva xerosis (KC), eye anaphylaxis illness is used in body gel single preparations of ephedrine, and its general tacrolimus ophthalmic by name is used in the body gel; English Tacrolimus In Situ Ophthalmic Gel by name; The Chinese phonetic alphabet is Takemosi Yanyong Zaitiningjiao.Medicine and main adjunct ingredient and the preparation of forming in following ratio that is applied to ophthalmology thereof; Wherein medicine is ground into impalpable powder or adopts solid dispersion technology or cyclodextrin inclusion technique to be prepared into the tacrolimus intermediate of high-dissolvability, adding ophthalmic gel base and other adjuvants are processed tacrolimus ophthalmic and are used in the body gel in the tacrolimus intermediate for preparing.
Tacrolimus ophthalmic of the present invention is used in the body gel preparation: said tacrolimus ophthalmic is used in the body gel preparation and contains the tacrolimus solid dispersion that water-soluble material is the high-dissolvability of carrier; According to mass fraction: 1 part of tacrolimus; 5～600 parts of water-solubility carrier materials; Said carrier material is polyvinylpyrrolidone, hydroxypropyl emthylcellulose, polyethylene glycols, poloxamer, Myrj 45, polyoxyethylene aliphatic alcohol ether, polyethylene glycol fatty acid glyceride, the mixture of one or more in saccharide or the organic acid.
The water-soluble material that contains of the present invention is the method for preparing that the tacrolimus ophthalmic of tacrolimus solid dispersion of the high-dissolvability of carrier is used in the body gel preparation; It is characterized in that: adopt solid dispersion technology to prepare the tacrolimus intermediate of high-dissolvability earlier, adding thickening agent and other adjuvants are processed tacrolimus ophthalmic and are used in the body gel in the tacrolimus intermediate for preparing.
Tacrolimus ophthalmic of the present invention is used in the body gel preparation: said tacrolimus ophthalmic is used in the tacrolimus clathrate that the body gel preparation contains with the cyclodextrin derivative high-dissolvability that is carrier; According to mass fraction: 1 part of tacrolimus; 5～600 parts of cyclodextrin derivative; Said cyclodextrin derivative is one or more the mixture in beta-schardinger dextrin-, methyl-beta-schardinger dextrin-, HP-, dihydroxypropyl-beta-schardinger dextrin-, glucose-beta-schardinger dextrin-, single succinyl-DM-, maleoyl-dimethyl-beta cyclodextrin, carboxymethyl cyclodextrin or the sulfoalkyl cyclodextrin.
Of the present invention containing with the cyclodextrin derivative is the method for preparing that the tacrolimus ophthalmic of tacrolimus clathrate of high-dissolvability of carrier is used in the body gel preparation; It is characterized in that: adopt cyclodextrin inclusion technique to prepare the tacrolimus intermediate of high-dissolvability earlier, adding thickening agent and other adjuvants are processed tacrolimus ophthalmic and are used in the body gel in the tacrolimus intermediate for preparing.
Of the present inventionly contain the method for preparing that the tacrolimus ophthalmic that is ground into the impalpable powder tacrolimus is used in the body gel preparation, it is characterized in that: earlier tacrolimus is ground into and adds thickening agent and other adjuvants behind the impalpable powder and process tacrolimus ophthalmic and be used in the body gel.
Remarkable advantage of the present invention is:
The present invention has overcome tacrolimus poorly water-soluble in the past; Problems such as the treatment window is narrow; Adopt solid dispersion technology or cyclodextrin inclusion technique or medicine such as is ground into behind the impalpable powder at solubilization method, significantly improve its dissolubility, thereby improve its bioavailability; Be prepared into then a kind of external for liquid condition, splash into the ophthalmic preparation of ophthalmic gel attitude.It is applied to the treatment of ophthalmic cornea graft-rejection, eye cornea and conjunctiva xerosis (KC), eye anaphylaxis illness etc.The present invention is prepared into eye with tacrolimus first and is used in the body gel, this gel for eye use external be liquid condition, dosage is accurately controlled easily, and is easy to use; Splashing into behind the ophthalmic can uniform spreading, and forms gel, within the eye the time of staying longer, be difficult for being diluted by tear; Can keep active drug concentration, enhancing treatment effect, and zest is little, good biocompatibility; Be that a kind of effective eye is used new drug, can be applied to clinically to have the wide development prospect.
Preferred cyclodextrin inclusion technique of the present invention is as the solubilization method of tacrolimus.Wherein, (HP-β-CD) solubilization to tacrolimus obviously is superior to other cyclodextrin derivative to HP-.With HP-β-CD is example, specifically inquires into the solubilization of cyclodextrin derivative to tacrolimus.The result shows, tacrolimus is had significant solubilization to HP-β-CD and along with the increase of HP-β-CD concentration, the dissolubility of medicine increases.In the time of 25 ℃, 5%HP-β-CD can make the dissolubility of tacrolimus in water increase 2.10 times; 50%HP-β-CD can make the dissolubility of tacrolimus in water increase 81.03 times.Along with the rising of temperature, the dissolubility of medicine also increases thereupon.When HP-β-CD mass concentration when being 50%, 25 ℃, 37 ℃ and 50 ℃ the dissolubility of tacrolimus be respectively 167.74,180.88 and 205.60 μ gml
-1Tacrolimus-HP-(dissolubility (like table 1) of HP-β-CD).When HP-β-CD mass concentration less than 30%, greater than 5% o'clock, the effect that prepared cyclodextrin clathrate redissolves was better, and the dissolubility of tacrolimus can satisfy the requirement of preparation.Characteristic of the present invention is, adopts HP-to prepare the tacrolimus cyclodextrin clathrate, and its concentration range is 5%～30%.
The dissolubility of table 1 tacrolimus in variable concentrations HP-β-CD aqueous solution
Description of drawings
Fig. 1 is the structural formula of tacrolimus.
The specific embodiment
It is that the tacrolimus ophthalmic of the tacrolimus solid dispersion of carrier is used in the body gel preparation that preparation contains with the water-soluble material:
The tacrolimus ophthalmic of tacrolimus solid dispersion that contains water-soluble material and be the high-dissolvability of carrier is used in body gel preparation method for preparing: adopt solid dispersion technology to prepare the tacrolimus intermediate of high-dissolvability earlier, in the tacrolimus intermediate for preparing, add responsive to temperature type gel-type vehicle and other adjuvants and process tacrolimus responsive to temperature type eye and be used in the body gel; Perhaps adopt pH responsive type gel-type vehicle to be prepared into tacrolimus pH responsive type eye and be used in the body gel; Perhaps adopt the ion-sensitive type gel-type vehicle to be prepared into tacrolimus ion-sensitive type eye and be used in the body gel; Perhaps adopt two kinds of machine-processed gel-type vehicles of different gellings to be prepared into tacrolimus mixed type eye and be used in the body gel.
Said preparation temperature responsive type eye is used in the body gel preparation:
(1) the first tacrolimus intermediate of preparation high-dissolvability: the raw material of said preparation tacrolimus intermediate comprises: according to mass fraction: 1 part of tacrolimus; 5～600 parts of responsive to temperature type gel-type vehicles; The preparation of employing solid dispersion technology; Described solid dispersion technology is solvent method, fusion method or solvent-fusion method: tacrolimus is dissolved in adequate amount of ethanol; Water-solubility carrier material after the adding fusion, mix homogeneously stirs; Pour out cooling rapidly, boulton process or freeze-drying are prepared into the tacrolimus intermediate of high-dissolvability;
(2) be dissolved in the injection water at the tacrolimus intermediate, antiseptic, isoosmotic adjusting agent, the viscosifier that prepare; Stirring makes the solubilizing agent complete wetting, is placed in 2～8 ℃ of refrigerators, until the solution that obtains clear; The responsive to temperature type gel-type vehicle that slowly adds accurate weighing while stirring; Continue to stir and to make responsive to temperature type gel-type vehicle granule, put it into then in 2～8 ℃ the refrigerator and preserve more than the 24h, until obtaining clarification, no agglomerate, finely dispersed solution all by water-wet; Regulate pH5～9 with the pH regulator agent, then with the filtration of 220 mesh sieve cloth, moisturizing is to total amount again, pressure sterilizing, and packing promptly gets.According to mass fraction: 1 part of tacrolimus; 5～600 parts of water-solubility carrier materials; 0～6 part of antiseptic; 2～200 parts of isoosmotic adjusting agent; 0～1000 part of viscosifier; 2～1000 parts of responsive to temperature type gel-type vehicles.Said pH regulator agent is to adopt sodium hydroxide, or one or more the mixture in hydrochloric acid, citric acid, sodium citrate, glacial acetic acid, boric acid, triethanol ammonium or the phosphate buffer; Said antiseptic is one or more the mixture in chlorobutanol, thimerosal, benzalkonium chloride, benzalkonium bromide, methyl hydroxybenzoate, ethyl hydroxybenzoate or the propylparaben etc.; Said isoosmotic adjusting agent is one or more the mixture in sodium chloride, glucose, mannitol, glycerol, sorbitol or the propylene glycol; Said viscosifier are one or more the mixture in hydroxypropyl emthylcellulose, methylcellulose, polyvidone or the polyvinyl alcohol; Said responsive to temperature type gel-type vehicle is poloxamer, polyethylene glycol-lactic acid block copolymer (PEG-PLGA (PLA)-PEG), ethylhydroxyethylcellulose or gather one or more the mixture in (N-isopropyl) acrylic acid amides.
Said preparation pH responsive type eye is used in the body gel preparation:
(1) the first tacrolimus intermediate of preparation high-dissolvability: the raw material of said preparation tacrolimus intermediate comprises: according to mass fraction: 1 part of tacrolimus; 5～600 parts of pH responsive type gel-type vehicles; The preparation of employing solid dispersion technology; Described solid dispersion technology is solvent method, fusion method or solvent-fusion method: tacrolimus is dissolved in adequate amount of ethanol; Water-solubility carrier material after the adding fusion, mix homogeneously stirs; Pour out cooling rapidly, boulton process or freeze-drying are prepared into the tacrolimus intermediate of high-dissolvability;
(2) pH responsive type gel-type vehicle and the viscosifier with accurate weighing constantly add in an amount of injection water under the stirring; Continuing to stir makes the two granule all wetted; Placement is until the solution of being clarified, do not have agglomerate; Slowly add tacrolimus intermediate, antiseptic, the isoosmotic adjusting agent for preparing while stirring, continue to stir until obtaining clarification, no agglomerate, finely dispersed solution; Regulate pH2.5～6 with the pH regulator agent, then with the filtration of 220 mesh sieve cloth, moisturizing is to total amount again, pressure sterilizing, and packing promptly gets.According to mass fraction: 1 part of tacrolimus; 5～600 parts of water-solubility carrier materials; 0～6 part of antiseptic; 2～200 parts of isoosmotic adjusting agent; 0～1000 part of viscosifier; 2～1000 parts of pH responsive type gel-type vehicles.Said pH regulator agent is to adopt sodium hydroxide, or one or more the mixture in hydrochloric acid, citric acid, sodium citrate, glacial acetic acid, boric acid, triethanol ammonium or the phosphate buffer; Said antiseptic is one or more the mixture in chlorobutanol, thimerosal, benzalkonium chloride, benzalkonium bromide, methyl hydroxybenzoate, ethyl hydroxybenzoate or the propylparaben etc.; Said isoosmotic adjusting agent is one or more the mixture in sodium chloride, glucose, mannitol, glycerol, sorbitol or the propylene glycol; Said viscosifier are one or more the mixture in hydroxypropyl emthylcellulose, methylcellulose, polyvidone or the polyvinyl alcohol; Said pH responsive type gel-type vehicle is one or more the mixture among carbomer, cross-linked acrylic acid and derivant thereof, chitosan and derivant thereof, cellulose acetate-phthalate, cellulose acetate phthalate ester (CAP) or the Lacte.
Said preparation ion-sensitive type eye is used in the body gel preparation:
(1) the first tacrolimus intermediate of preparation high-dissolvability: the raw material of said preparation tacrolimus intermediate comprises: according to mass fraction: 1 part of tacrolimus; 5～600 parts of ion-sensitive type gel-type vehicles; The preparation of employing solid dispersion technology; Described solid dispersion technology is solvent method, fusion method or solvent-fusion method: tacrolimus is dissolved in adequate amount of ethanol; Water-solubility carrier material after the adding fusion, mix homogeneously stirs; Pour out cooling rapidly, boulton process or freeze-drying are prepared into the tacrolimus intermediate of high-dissolvability;
(2) ion-sensitive type gel-type vehicle and the viscosifier with accurate weighing constantly add in an amount of injection water under the stirring, continue to stir to make the two granule all wetted, and placement is until the solution of being clarified, do not have agglomerate; Slowly add tacrolimus intermediate, antiseptic, the isoosmotic adjusting agent for preparing while stirring; Continue to stir until obtaining clarification, no agglomerate, finely dispersed solution, regulate pH5～9, filter with 220 mesh sieve cloth then with the pH regulator agent; Moisturizing is to total amount again; Pressure sterilizing, packing promptly gets.According to mass fraction: 1 part of tacrolimus; 5～600 parts of water-solubility carrier materials; 0～6 part of antiseptic; 2～200 parts of isoosmotic adjusting agent; 0～1000 part of viscosifier; 2～1000 parts of ion-sensitive type gel-type vehicles.Said pH regulator agent is to adopt sodium hydroxide, or one or more the mixture in hydrochloric acid, citric acid, sodium citrate, glacial acetic acid, boric acid, triethanol ammonium or the phosphate buffer; Said antiseptic is one or more the mixture in chlorobutanol, thimerosal, benzalkonium chloride, benzalkonium bromide, methyl hydroxybenzoate, ethyl hydroxybenzoate or the propylparaben etc.; Said isoosmotic adjusting agent is one or more the mixture in sodium chloride, glucose, mannitol, glycerol, sorbitol or the propylene glycol; Said viscosifier are one or more the mixture in hydroxypropyl emthylcellulose, methylcellulose, polyvidone or the polyvinyl alcohol; Said ion-sensitive type gel-type vehicle is one or more the mixture in acetyl-removed gellan gum or alginate and the polysaccharide.
Said preparation mixed type eye is used in body gel preparation one:
(1) the first tacrolimus intermediate of preparation high-dissolvability: the raw material of said preparation tacrolimus intermediate comprises: according to mass fraction: 1 part of tacrolimus; 5～600 parts of ion-sensitive type gel-type vehicles; The preparation of employing solid dispersion technology; Described solid dispersion technology is solvent method, fusion method or solvent-fusion method: tacrolimus is dissolved in adequate amount of ethanol; Water-solubility carrier material after the adding fusion, mix homogeneously stirs; Pour out cooling rapidly, boulton process or freeze-drying are prepared into the tacrolimus intermediate of high-dissolvability;
(2) the pH responsive type gel-type vehicle with accurate weighing constantly adds in an amount of injection water under the stirring; Responsive to temperature type gel-type vehicle with accurate weighing constantly adds in an amount of injection water under the stirring in addition; Continuing to stir makes pH responsive type gel-type vehicle granule all wetted; Placement is until the solution of being clarified, do not have agglomerate, the responsive to temperature type gel-type vehicle put into 2～8 ℃ refrigerator and preserved more than the 24h, until obtaining clarification, no agglomerate, finely dispersed solution; Slowly add tacrolimus intermediate, antiseptic, the isoosmotic adjusting agent prepare while stirring, continue to stir until obtaining clarification, no agglomerate, finely dispersed solution, then with the filtration of 220 mesh sieve cloth, moisturizing is to total amount again, pressure sterilizing, and packing promptly gets.According to mass fraction: 1 part of tacrolimus; 5～600 parts of water-solubility carrier materials; 0～6 part of antiseptic; 2～200 parts of isoosmotic adjusting agent; 2～1000 parts of ion-sensitive type gel-type vehicles; 2～1000 parts of responsive to temperature type gel-type vehicles.Said pH regulator agent is to adopt sodium hydroxide, or one or more the mixture in hydrochloric acid, citric acid, sodium citrate, glacial acetic acid, boric acid, triethanol ammonium or the phosphate buffer; Said antiseptic is one or more the mixture in chlorobutanol, thimerosal, benzalkonium chloride, benzalkonium bromide, methyl hydroxybenzoate, ethyl hydroxybenzoate or the propylparaben etc.; Said isoosmotic adjusting agent is one or more the mixture in sodium chloride, glucose, mannitol, glycerol, sorbitol or the propylene glycol; Said pH responsive type gel-type vehicle is one or more the mixture among carbomer, cross-linked acrylic acid and derivant thereof, chitosan and derivant thereof, cellulose acetate-phthalate, cellulose acetate phthalate ester (CAP) or the Lacte; Said responsive to temperature type gel-type vehicle is poloxamer, polyethylene glycol-lactic acid block copolymer (PEG-PLGA (PLA)-PEG), ethylhydroxyethylcellulose or gather one or more the mixture in (N-isopropyl) acrylic acid amides.
Said preparation mixed type eye is used in body gel preparation two:
(1) the first tacrolimus intermediate of preparation high-dissolvability: the raw material of said preparation tacrolimus intermediate comprises: according to mass fraction: 1 part of tacrolimus; 5～600 parts of ion-sensitive type gel-type vehicles; The preparation of employing solid dispersion technology; Described solid dispersion technology is solvent method, fusion method or solvent-fusion method: tacrolimus is dissolved in adequate amount of ethanol; Water-solubility carrier material after the adding fusion, mix homogeneously stirs; Pour out cooling rapidly, boulton process or freeze-drying are prepared into the tacrolimus intermediate of high-dissolvability;
(2) the ion-sensitive type gel-type vehicle with accurate weighing constantly adds in an amount of injection water under the stirring; Responsive to temperature type gel-type vehicle with accurate weighing constantly adds in an amount of injection water under the stirring in addition; Continuing to stir makes ion-sensitive type gel-type vehicle granule all wetted; Placement is until the solution of being clarified, do not have agglomerate, the responsive to temperature type gel-type vehicle put into 2～8 ℃ refrigerator and preserved more than the 24h, until obtaining clarification, no agglomerate, finely dispersed solution; Slowly add tacrolimus intermediate, antiseptic, the isoosmotic adjusting agent prepare while stirring, continue to stir until obtaining clarification, no agglomerate, finely dispersed solution, then with the filtration of 220 mesh sieve cloth, moisturizing is to total amount again, pressure sterilizing, and packing promptly gets.Above raw material is according to mass fraction: 1 part of tacrolimus; 5～600 parts of water-solubility carrier materials; 0～6 part of antiseptic; 2～200 parts of isoosmotic adjusting agent; 2～1000 parts of ion-sensitive type gel-type vehicles; 2～1000 parts of responsive to temperature type gel-type vehicles.Said pH regulator agent is to adopt sodium hydroxide, or one or more the mixture in hydrochloric acid, citric acid, sodium citrate, glacial acetic acid, boric acid, triethanol ammonium or the phosphate buffer; Said antiseptic is one or more the mixture in chlorobutanol, thimerosal, benzalkonium chloride, benzalkonium bromide, methyl hydroxybenzoate, ethyl hydroxybenzoate or the propylparaben etc.; Said isoosmotic adjusting agent is one or more the mixture in sodium chloride, glucose, mannitol, glycerol, sorbitol or the propylene glycol; Said ion-sensitive type gel-type vehicle is one or more the mixture in acetyl-removed gellan gum or alginate and the polysaccharide thereof; Said responsive to temperature type gel-type vehicle is poloxamer, polyethylene glycol-lactic acid block copolymer (PEG-PLGA (PLA)-PEG), ethylhydroxyethylcellulose or gather one or more the mixture in (N-isopropyl) acrylic acid amides.
It is that the tacrolimus ophthalmic of tacrolimus clathrate of carrier is used in the body gel preparation that preparation contains with the cyclodextrin derivative:
The tacrolimus ophthalmic of tacrolimus clathrate that contains cyclodextrin derivative and be the high-dissolvability of carrier is used in body gel preparation method for preparing: adopt cyclodextrin inclusion technique to prepare the tacrolimus intermediate of high-dissolvability earlier, in the tacrolimus intermediate for preparing, add responsive to temperature type gel-type vehicle and other adjuvants and process tacrolimus responsive to temperature type eye and be used in the body gel; Perhaps adopt pH responsive type gel-type vehicle to be prepared into tacrolimus pH responsive type eye and be used in the body gel; Perhaps adopt the ion-sensitive type gel-type vehicle to be prepared into tacrolimus ion-sensitive type eye and be used in the body gel; Perhaps adopt two kinds of machine-processed gel-type vehicles of different gellings to be prepared into tacrolimus mixed type eye and be used in the body gel.
Said preparation temperature responsive type eye is used in the body gel preparation:
(1) the first tacrolimus intermediate of preparation high-dissolvability: the raw material of said preparation tacrolimus intermediate comprises: according to mass fraction: 1 part of tacrolimus; 5～600 parts of cyclodextrin derivative; The preparation of employing cyclodextrin inclusion technique; Described cyclodextrin inclusion technique is paddling process, microwave method or supercritical ultrasonics technology: tacrolimus and cyclodextrin derivative are dissolved in adequate amount of ethanol; Sonic oscillation 5～60min; Rotary Evaporators is 20～60 ℃ of solvent evaporated, and boulton process or freeze-drying are prepared into the tacrolimus intermediate of high-dissolvability;
(2) be dissolved in the injection water at the tacrolimus intermediate, antiseptic, isoosmotic adjusting agent, the viscosifier that prepare; Be placed in 2～8 ℃ of refrigerators; Until the solution that obtains clear, slowly add the responsive to temperature type gel-type vehicle of accurate weighing while stirring, continue stirring and make responsive to temperature type gel-type vehicle granule all by water-wet; Put it into then and preserve more than the 24h, in 2～8 ℃ the refrigerator until obtaining clarification, no agglomerate, finely dispersed solution; Regulate pH5～9 with the pH regulator agent, then with the filtration of 220 mesh sieve cloth, moisturizing is to total amount again, pressure sterilizing, and packing promptly gets.According to mass fraction: 1 part of tacrolimus; 5～600 parts of cyclodextrin derivative; 0～6 part of antiseptic; 2～200 parts of isoosmotic adjusting agent; 0～1000 part of viscosifier; 2～1000 parts of responsive to temperature type gel-type vehicles.Said pH regulator agent is to adopt sodium hydroxide, or one or more the mixture in hydrochloric acid, citric acid, sodium citrate, glacial acetic acid, boric acid, triethanol ammonium or the phosphate buffer; Said antiseptic is one or more the mixture in chlorobutanol, thimerosal, benzalkonium chloride, benzalkonium bromide, methyl hydroxybenzoate, ethyl hydroxybenzoate or the propylparaben etc.; Said isoosmotic adjusting agent is one or more the mixture in sodium chloride, glucose, mannitol, glycerol, sorbitol or the propylene glycol; Said viscosifier are one or more the mixture in hydroxypropyl emthylcellulose, methylcellulose, polyvidone or the polyvinyl alcohol; Said responsive to temperature type gel-type vehicle is poloxamer, polyethylene glycol-lactic acid block copolymer (PEG-PLGA (PLA)-PEG), ethylhydroxyethylcellulose or gather one or more the mixture in (N-isopropyl) acrylic acid amides.
Said preparation pH responsive type eye is used in the body gel preparation:
(1) the first tacrolimus intermediate of preparation high-dissolvability: the raw material of said preparation tacrolimus intermediate comprises: according to mass fraction: 1 part of tacrolimus; 5～600 parts of cyclodextrin derivative; The preparation of employing cyclodextrin inclusion technique; Described cyclodextrin inclusion technique is paddling process, microwave method or supercritical ultrasonics technology: tacrolimus and cyclodextrin derivative are dissolved in adequate amount of ethanol; Sonic oscillation 5～60min; Rotary Evaporators is 20～60 ℃ of solvent evaporated, and boulton process or freeze-drying are prepared into the tacrolimus intermediate of high-dissolvability;
(2) pH responsive type gel-type vehicle and the viscosifier with accurate weighing constantly add in an amount of injection water under the stirring; Continuing to stir makes the two granule all wetted; Placement is until the solution of being clarified, do not have agglomerate; Slowly add tacrolimus intermediate, antiseptic, the isoosmotic adjusting agent for preparing while stirring, continue to stir until obtaining clarification, no agglomerate, finely dispersed solution; Regulate pH2.5～6 with the pH regulator agent, then with the filtration of 220 mesh sieve cloth, moisturizing is to total amount again, pressure sterilizing, and packing promptly gets.According to mass fraction: 1 part of tacrolimus; 5～600 parts of water-solubility carrier materials; 0～6 part of antiseptic; 2～200 parts of isoosmotic adjusting agent; 0～1000 part of viscosifier; 2～1000 parts of pH responsive type gel-type vehicles.Said pH regulator agent is to adopt sodium hydroxide, or one or more the mixture in hydrochloric acid, citric acid, sodium citrate, glacial acetic acid, boric acid, triethanol ammonium or the phosphate buffer; Said antiseptic is one or more the mixture in chlorobutanol, thimerosal, benzalkonium chloride, benzalkonium bromide, methyl hydroxybenzoate, ethyl hydroxybenzoate or the propylparaben etc.; Said isoosmotic adjusting agent is one or more the mixture in sodium chloride, glucose, mannitol, glycerol, sorbitol or the propylene glycol; Said viscosifier are one or more the mixture in hydroxypropyl emthylcellulose, methylcellulose, polyvidone or the polyvinyl alcohol; Said pH responsive type gel-type vehicle is one or more the mixture among carbomer, cross-linked acrylic acid and derivant thereof, chitosan and derivant thereof, cellulose acetate-phthalate, cellulose acetate phthalate ester (CAP) or the Lacte.
Said preparation ion-sensitive type eye is used in the body gel preparation:
(1) the first tacrolimus intermediate of preparation high-dissolvability: the raw material of said preparation tacrolimus intermediate comprises: according to mass fraction: 1 part of tacrolimus; 5～600 parts of cyclodextrin derivative; The preparation of employing cyclodextrin inclusion technique; Described cyclodextrin inclusion technique is paddling process, microwave method or supercritical ultrasonics technology: tacrolimus and cyclodextrin derivative are dissolved in adequate amount of ethanol; Sonic oscillation 5～60min; Rotary Evaporators is 20～60 ℃ of solvent evaporated, and boulton process or freeze-drying are prepared into the tacrolimus intermediate of high-dissolvability;
(2) ion-sensitive type gel-type vehicle and the viscosifier with accurate weighing constantly add in an amount of injection water under the stirring, continue to stir to make the two granule all wetted, and placement is until the solution of being clarified, do not have agglomerate; Slowly add tacrolimus intermediate, antiseptic, the isoosmotic adjusting agent for preparing while stirring; Continue to stir until obtaining clarification, no agglomerate, finely dispersed solution, regulate pH5～9, filter with 220 mesh sieve cloth then with the pH regulator agent; Moisturizing is to total amount again; Pressure sterilizing, packing promptly gets.According to mass fraction: 1 part of tacrolimus; 5～600 parts of water-solubility carrier materials; 0～6 part of antiseptic; 2～200 parts of isoosmotic adjusting agent; 0～1000 part of viscosifier; 2～1000 parts of ion-sensitive type gel-type vehicles.Said pH regulator agent is to adopt sodium hydroxide, or one or more the mixture in hydrochloric acid, citric acid, sodium citrate, glacial acetic acid, boric acid, triethanol ammonium or the phosphate buffer; Said antiseptic is one or more the mixture in chlorobutanol, thimerosal, benzalkonium chloride, benzalkonium bromide, methyl hydroxybenzoate, ethyl hydroxybenzoate or the propylparaben etc.; Said isoosmotic adjusting agent is one or more the mixture in sodium chloride, glucose, mannitol, glycerol, sorbitol or the propylene glycol; Said viscosifier are one or more the mixture in hydroxypropyl emthylcellulose, methylcellulose, polyvidone or the polyvinyl alcohol; Said ion-sensitive type gel-type vehicle is one or more the mixture in acetyl-removed gellan gum or alginate and the polysaccharide thereof.
Said preparation mixed type eye is used in body gel preparation one:
(1) the first tacrolimus intermediate of preparation high-dissolvability: the raw material of said preparation tacrolimus intermediate comprises: according to mass fraction: 1 part of tacrolimus; 5～600 parts of cyclodextrin derivative; The preparation of employing cyclodextrin inclusion technique; Described cyclodextrin inclusion technique is paddling process, microwave method or supercritical ultrasonics technology: tacrolimus and cyclodextrin derivative are dissolved in adequate amount of ethanol; Sonic oscillation 5～60min; Rotary Evaporators is 20～60 ℃ of solvent evaporated, and boulton process or freeze-drying are prepared into the tacrolimus intermediate of high-dissolvability;
(2) the pH responsive type gel-type vehicle with accurate weighing constantly adds in an amount of injection water under the stirring, continues to stir to make pH responsive type gel-type vehicle granule all wetted, and placement is until the solution of being clarified, do not have agglomerate; Responsive to temperature type gel-type vehicle with accurate weighing constantly adds in an amount of injection water under the stirring in addition, the responsive to temperature type gel-type vehicle is put into 2～8 ℃ refrigerator and is preserved more than the 24h, until obtaining clarification, no agglomerate, finely dispersed solution; With responsive to temperature type gel-type vehicle and pH responsive type gel-type vehicle mix homogeneously, slowly add tacrolimus intermediate, antiseptic, the isoosmotic adjusting agent for preparing while stirring, continue to stir until obtaining clarification, no agglomerate, finely dispersed solution; Regulate pH2.5～6 with the pH regulator agent; Filter with 220 mesh sieve cloth then, moisturizing is to total amount again, pressure sterilizing; Packing promptly gets.According to mass fraction: 1 part of tacrolimus; 5～600 parts of water-solubility carrier materials; 0～6 part of antiseptic; 2～200 parts of isoosmotic adjusting agent; 2～1000 parts of ion-sensitive type gel-type vehicles; 2～1000 parts of responsive to temperature type gel-type vehicles.Said pH regulator agent is to adopt sodium hydroxide, or one or more the mixture in hydrochloric acid, citric acid, sodium citrate, glacial acetic acid, boric acid, triethanol ammonium or the phosphate buffer; Said antiseptic is one or more the mixture in chlorobutanol, thimerosal, benzalkonium chloride, benzalkonium bromide, methyl hydroxybenzoate, ethyl hydroxybenzoate or the propylparaben etc.; Said isoosmotic adjusting agent is one or more the mixture in sodium chloride, glucose, mannitol, glycerol, sorbitol or the propylene glycol; Said pH responsive type gel-type vehicle is one or more the mixture among carbomer, cross-linked acrylic acid and derivant thereof, chitosan and derivant thereof, cellulose acetate-phthalate, cellulose acetate phthalate ester (CAP) or the Lacte; Said responsive to temperature type gel-type vehicle is poloxamer, polyethylene glycol-lactic acid block copolymer (PEG-PLGA (PLA)-PEG), ethylhydroxyethylcellulose or gather one or more the mixture in (N-isopropyl) acrylic acid amides.
Said preparation mixed type eye is used in body gel preparation two:
(1) the first tacrolimus intermediate of preparation high-dissolvability: the raw material of said preparation tacrolimus intermediate comprises: according to mass fraction: 1 part of tacrolimus; 5～600 parts of cyclodextrin derivative; The preparation of employing cyclodextrin inclusion technique; Described cyclodextrin inclusion technique is paddling process, microwave method or supercritical ultrasonics technology: tacrolimus and cyclodextrin derivative are dissolved in adequate amount of ethanol; Sonic oscillation 5～60min; Rotary Evaporators is 20～60 ℃ of solvent evaporated, and boulton process or freeze-drying are prepared into the tacrolimus intermediate of high-dissolvability;
(2) the ion-sensitive type gel-type vehicle with accurate weighing constantly adds in an amount of injection water under the stirring, continues to stir to make ion-sensitive type gel-type vehicle granule all wetted, and placement is until the solution of being clarified, do not have agglomerate; Responsive to temperature type gel-type vehicle with accurate weighing constantly adds in an amount of injection water under the stirring in addition, the responsive to temperature type gel-type vehicle is put into 2～8 ℃ refrigerator and is preserved more than the 24h, until obtaining clarification, no agglomerate, finely dispersed solution; With responsive to temperature type gel-type vehicle and pH responsive type gel-type vehicle mix homogeneously, slowly add tacrolimus intermediate, antiseptic, the isoosmotic adjusting agent for preparing while stirring, continue to stir until obtaining clarification, no agglomerate, finely dispersed solution; Regulate pH5～9 with the pH regulator agent; Filter with 220 mesh sieve cloth then, moisturizing is to total amount again, pressure sterilizing; Packing promptly gets.According to mass fraction: 1 part of tacrolimus; 5～600 parts of water-solubility carrier materials; 0～6 part of antiseptic; 2～200 parts of isoosmotic adjusting agent; 2～1000 parts of ion-sensitive type gel-type vehicles; 2～1000 parts of responsive to temperature type gel-type vehicles.Said pH regulator agent is to adopt sodium hydroxide, or one or more the mixture in hydrochloric acid, citric acid, sodium citrate, glacial acetic acid, boric acid, triethanol ammonium or the phosphate buffer; Said antiseptic is one or more the mixture in chlorobutanol, thimerosal, benzalkonium chloride, benzalkonium bromide, methyl hydroxybenzoate, ethyl hydroxybenzoate or the propylparaben etc.; Said isoosmotic adjusting agent is one or more the mixture in sodium chloride, glucose, mannitol, glycerol, sorbitol or the propylene glycol; Said ion-sensitive type gel-type vehicle is one or more the mixture in acetyl-removed gellan gum or alginate and the polysaccharide thereof; Said responsive to temperature type gel-type vehicle is poloxamer, polyethylene glycol-lactic acid block copolymer (PEG-PLGA (PLA)-PEG), ethylhydroxyethylcellulose or gather one or more the mixture in (N-isopropyl) acrylic acid amides.
Preparation contains the tacrolimus ophthalmic that is ground into impalpable powder and is used in the body gel preparation:
Contain the tacrolimus ophthalmic that is ground into impalpable powder and be used in body gel preparation method for preparing: earlier tacrolimus is ground into impalpable powder, crosses 220 mesh sieves, add responsive to temperature type gel-type vehicle and other adjuvants respectively and process tacrolimus responsive to temperature type eye and be used in the body gel; Perhaps adopt pH responsive type gel-type vehicle to be prepared into tacrolimus pH responsive type eye and be used in the body gel; Perhaps adopt the ion-sensitive type gel-type vehicle to be prepared into tacrolimus ion-sensitive type eye and be used in the body gel; Perhaps adopt two kinds of machine-processed gel-type vehicles of different gellings to be prepared into tacrolimus mixed type eye and be used in the body gel.
Said preparation temperature responsive type eye is used in the body gel preparation:
Antiseptic, isoosmotic adjusting agent, the viscosifier of getting recipe quantity are dissolved in the injection water; Be placed in 2～8 ℃ of refrigerators; Until the solution that obtains clear, slowly add the responsive to temperature type gel-type vehicle of accurate weighing while stirring, continue stirring and make responsive to temperature type gel-type vehicle granule all by water-wet; Put it into then and preserve more than the 24h, in 2～8 ℃ the refrigerator until obtaining clarification, no agglomerate, finely dispersed gel-type vehicle; The tacrolimus of recipe quantity is ground into impalpable powder, crosses 220 mesh sieves, gradation is ground in the substrate, stirs, and regulates pH5～9 with the pH regulator agent, and then with the filtration of 220 mesh sieve cloth, moisturizing is to total amount again, pressure sterilizing, and packing promptly gets.According to mass fraction: 1 part of tacrolimus; 0.2～6 part of antiseptic; 2～200 parts of isoosmotic adjusting agent; 0～1000 part of viscosifier; 2～1000 parts of responsive to temperature type gel-type vehicles.Said pH regulator agent is to adopt sodium hydroxide, or one or more the mixture in hydrochloric acid, citric acid, sodium citrate, glacial acetic acid, boric acid, triethanol ammonium or the phosphate buffer; Said antiseptic is one or more the mixture in chlorobutanol, thimerosal, benzalkonium chloride, benzalkonium bromide, Metagin, second or the propyl ester etc.; Said isoosmotic adjusting agent is one or more the mixture in sodium chloride, glucose, mannitol, glycerol, sorbitol or the propylene glycol; Said viscosifier are one or more the mixture in hydroxypropyl emthylcellulose, methylcellulose, polyvidone or the polyvinyl alcohol; Said responsive to temperature type gel-type vehicle is poloxamer, polyethylene glycol-lactic acid block copolymer (PEG-PLGA (PLA)-PEG), ethylhydroxyethylcellulose or gather one or more the mixture in (N-isopropyl) acrylic acid amides.
Said preparation pH responsive type eye is used in the body gel preparation:
The pH responsive type gel-type vehicle and the viscosifier of accurate weighing are constantly added in an amount of injection water under the stirring, and continuation is stirred and is made the two granule all wetted, and placement is until the solution of being clarified, do not have agglomerate; The tacrolimus of recipe quantity is ground into impalpable powder; Cross 220 mesh sieves, gradation is ground in the substrate, stirs; Slowly add antiseptic, isoosmotic adjusting agent while stirring, continue to stir until obtaining clarification, no agglomerate, finely dispersed solution; Regulate pH2.5～6 with the pH regulator agent, then with the filtration of 220 mesh sieve cloth, moisturizing is to total amount again, pressure sterilizing, and packing promptly gets.According to mass fraction: 1 part of tacrolimus; 5～600 parts of water-solubility carrier materials; 0～6 part of antiseptic; 2～200 parts of isoosmotic adjusting agent; 0～1000 part of viscosifier; 2～1000 parts of pH responsive type gel-type vehicles.Said pH regulator agent is to adopt sodium hydroxide, or one or more the mixture in hydrochloric acid, citric acid, sodium citrate, glacial acetic acid, boric acid, triethanol ammonium or the phosphate buffer; Said antiseptic is one or more the mixture in chlorobutanol, thimerosal, benzalkonium chloride, benzalkonium bromide, methyl hydroxybenzoate, ethyl hydroxybenzoate or the propylparaben etc.; Said isoosmotic adjusting agent is one or more the mixture in sodium chloride, glucose, mannitol, glycerol, sorbitol or the propylene glycol; Said viscosifier are one or more the mixture in hydroxypropyl emthylcellulose, methylcellulose, polyvidone or the polyvinyl alcohol; Said pH responsive type gel-type vehicle is one or more the mixture among carbomer, cross-linked acrylic acid and derivant thereof, chitosan and derivant thereof, cellulose acetate-phthalate, cellulose acetate phthalate ester (CAP) or the Lacte.
Said preparation ion-sensitive type eye is used in the body gel preparation:
The ion-sensitive type gel-type vehicle and the viscosifier of accurate weighing are constantly added in an amount of injection water under the stirring, and continuation is stirred and is made the two granule all wetted, and placement is until the solution of being clarified, do not have agglomerate; The tacrolimus of recipe quantity is ground into impalpable powder, crosses 220 mesh sieves, gradation is ground in the substrate; Stir, slowly add antiseptic, isoosmotic adjusting agent while stirring, continue to stir until obtaining clarification, no agglomerate, finely dispersed solution; Regulate pH5～9 with the pH regulator agent, filter with 220 mesh sieve cloth then, moisturizing is to total amount again; Pressure sterilizing, packing promptly gets.According to mass fraction: 1 part of tacrolimus; 5～600 parts of water-solubility carrier materials; 0～6 part of antiseptic; 2～200 parts of isoosmotic adjusting agent; 0～1000 part of viscosifier; 2～1000 parts of ion-sensitive type gel-type vehicles.Said pH regulator agent is to adopt sodium hydroxide, or one or more the mixture in hydrochloric acid, citric acid, sodium citrate, glacial acetic acid, boric acid, triethanol ammonium or the phosphate buffer; Said antiseptic is one or more the mixture in chlorobutanol, thimerosal, benzalkonium chloride, benzalkonium bromide, methyl hydroxybenzoate, ethyl hydroxybenzoate or the propylparaben etc.; Said isoosmotic adjusting agent is one or more the mixture in sodium chloride, glucose, mannitol, glycerol, sorbitol or the propylene glycol; Said viscosifier are one or more the mixture in hydroxypropyl emthylcellulose, methylcellulose, polyvidone or the polyvinyl alcohol; Said ion-sensitive type gel-type vehicle is one or more the mixture in acetyl-removed gellan gum or alginate and the polysaccharide thereof.
Said preparation mixed type eye is used in body gel preparation one:
The pH responsive type gel-type vehicle of accurate weighing is constantly added in an amount of injection water under the stirring, and continuation is stirred and is made pH responsive type gel-type vehicle granule all wetted, and placement is until the solution of being clarified, do not have agglomerate; Responsive to temperature type gel-type vehicle with accurate weighing constantly adds in an amount of injection water under the stirring in addition, the responsive to temperature type gel-type vehicle is put into 2～8 ℃ refrigerator and is preserved more than the 24h, until obtaining clarification, no agglomerate, finely dispersed solution; With responsive to temperature type gel-type vehicle and pH responsive type gel-type vehicle mix homogeneously, the tacrolimus of recipe quantity is ground into impalpable powder, cross 220 mesh sieves, gradation is ground in the substrate; Stir, slowly add antiseptic, isoosmotic adjusting agent while stirring, continue to stir until obtaining clarification, no agglomerate, finely dispersed solution; Regulate pH2.5～6 with the pH regulator agent, filter with 220 mesh sieve cloth then, moisturizing is to total amount again; Pressure sterilizing, packing promptly gets.According to mass fraction: 1 part of tacrolimus; 5～600 parts of water-solubility carrier materials; 0～6 part of antiseptic; 2～200 parts of isoosmotic adjusting agent; 2～1000 parts of ion-sensitive type gel-type vehicles; 2～1000 parts of responsive to temperature type gel-type vehicles.Said pH regulator agent is to adopt sodium hydroxide, or one or more the mixture in hydrochloric acid, citric acid, sodium citrate, glacial acetic acid, boric acid, triethanol ammonium or the phosphate buffer; Said antiseptic is one or more the mixture in chlorobutanol, thimerosal, benzalkonium chloride, benzalkonium bromide, methyl hydroxybenzoate, ethyl hydroxybenzoate or the propylparaben etc.; Said isoosmotic adjusting agent is one or more the mixture in sodium chloride, glucose, mannitol, glycerol, sorbitol or the propylene glycol; Said pH responsive type gel-type vehicle is one or more the mixture among carbomer, cross-linked acrylic acid and derivant thereof, chitosan and derivant thereof, cellulose acetate-phthalate, cellulose acetate phthalate ester (CAP) or the Lacte; Said responsive to temperature type gel-type vehicle is poloxamer, polyethylene glycol-lactic acid block copolymer (PEG-PLGA (PLA)-PEG), ethylhydroxyethylcellulose or gather one or more the mixture in (N-isopropyl) acrylic acid amides.
Said preparation mixed type eye is used in body gel preparation two:
The ion-sensitive type gel-type vehicle of accurate weighing is constantly added in an amount of injection water under the stirring, and continuation is stirred and is made ion-sensitive type gel-type vehicle granule all wetted, and placement is until the solution of being clarified, do not have agglomerate; Responsive to temperature type gel-type vehicle with accurate weighing constantly adds in an amount of injection water under the stirring in addition, the responsive to temperature type gel-type vehicle is put into 2～8 ℃ refrigerator and is preserved more than the 24h, until obtaining clarification, no agglomerate, finely dispersed solution; With responsive to temperature type gel-type vehicle and ion-sensitive type gel-type vehicle mix homogeneously, slowly add tacrolimus impalpable powder, antiseptic, the isoosmotic adjusting agent of mistake 220 mesh sieves that prepare while stirring, continue to stir until obtaining clarification, no agglomerate, finely dispersed solution; Regulate pH2.5～6 with the pH regulator agent; Filter with 220 mesh sieve cloth then, moisturizing is to total amount again, pressure sterilizing; Packing promptly gets.According to mass fraction: 1 part of tacrolimus; 5～600 parts of water-solubility carrier materials; 0～6 part of antiseptic; 2～200 parts of isoosmotic adjusting agent; 2～1000 parts of ion-sensitive type gel-type vehicles; 2～1000 parts of responsive to temperature type gel-type vehicles.Said pH regulator agent is to adopt sodium hydroxide, or one or more the mixture in hydrochloric acid, citric acid, sodium citrate, glacial acetic acid, boric acid, triethanol ammonium or the phosphate buffer; Said antiseptic is one or more the mixture in chlorobutanol, thimerosal, benzalkonium chloride, benzalkonium bromide, methyl hydroxybenzoate, ethyl hydroxybenzoate or the propylparaben etc.; Said isoosmotic adjusting agent is one or more the mixture in sodium chloride, glucose, mannitol, glycerol, sorbitol or the propylene glycol; Said ion-sensitive type gel-type vehicle is one or more the mixture in acetyl-removed gellan gum or alginate and the polysaccharide thereof; Said responsive to temperature type gel-type vehicle is poloxamer, polyethylene glycol-lactic acid block copolymer (PEG-PLGA (PLA)-PEG), ethylhydroxyethylcellulose or gather one or more the mixture in (N-isopropyl) acrylic acid amides.
Tacrolimus ophthalmic of the present invention is used in the physicochemical character of body gel:
External be liquid, splashing into ophthalmic becomes gel, viscosity reduces with the increase of external carbuncle.
It is a kind of in external one-tenth liquid condition that tacrolimus ophthalmic of the present invention is used in the body gel preparation, splashes into the ophthalmic preparation of ophthalmic gel attitude.Its toxicity is low, and zest is little, good biocompatibility, and patient's compliance and toleration improve in section.Development and exploitation that tacrolimus ophthalmic is used in the body gel preparation have following advantage: for liquid condition, dosage is accurately control, easy to use easily, and be easy to sprawl after splashing into ophthalmic external for (1) these article.(2) eye of the present invention is used in the body gel and on rheology, is plasticity or pseudoplastic behavior character, and viscosity reduces with nictation, and use feeling is comfortable, when not batting an eyelid, can recover viscosity again.(3) the tacrolimus gel for eye use directly acts on the affected part, can play a role fully effectively, can reduce GI irritation, neurotoxicity and other side effect that oral drugs cause.(4) compare with conventional dosage forms commonly used, have unrivaled advantage.Compare with eye drop, tacrolimus ophthalmic is used in the body gel preparation and is difficult for by the tear dilution, and prolong drug helped medicine and keeps higher concentration at anterior corneal surface in the holdup time of eye, increased the medication amount through cornea, improved bioavailability of medicament; Compare with eye ointment, tacrolimus ophthalmic is used in body gel good water solubility, cleans easily, not pollution clothes.On the other hand, tacrolimus ophthalmic is used in the body gel and does not cause the visual field fuzzy, uses the back to form the gas-pervious reticular membrane of one deck, all can use round the clock.This Products Development is successful, not only can fill up the blank of domestic and international ophthalmic remedy, also can bring good society and economic benefit.
The representational embodiment of preparation of the present invention is provided below, and these embodiment only are used to explain the present invention, and protection domain are not caused restriction.
Embodiment
Embodiment 1 tacrolimus responsive to temperature type eye is used in the preparation of body gel
| Tacrolimus | 0.05g |
| HP- | 0.70g |
| Poloxamer 407 (P407) | 20.0g |
| Poloxamer 188 (P188) | 10.3g |
| Sodium chloride | 0.9g |
| Benzalkonium bromide | 0.02g |
| Using the 0.1mol/L sodium hydroxide to regulate pH is 8 | |
| Add water to full dose | 100g |
Preparation technology:
Get tacrolimus and be dissolved in the small amount of ethanol solution, on one side ultrasonic one side slowly join in the HP-aqueous solution, ultrasonic 40min, lyophilized overnight promptly gets.Tacrolimus hydroxypropyl-beta-cyclodextrin inclusion, sodium chloride, the benzalkonium bromide of recipe quantity are dissolved in the injection water, are placed in 2～8 ℃ of refrigerators, until the solution that obtains clear; The poloxamer that slowly adds accurate weighing while stirring continue to stir and to make the poloxamer granule all by water-wet, puts it into then in 2～8 ℃ the refrigerator to preserve more than the 24h; Until obtaining clarification, no agglomerate, finely dispersed solution, using the 0.1mol/L sodium hydroxide to regulate pH is 8, filters with 220 mesh sieve cloth then; Moisturizing is to total amount again; Pressure sterilizing, packing promptly gets.
Embodiment 2 tacrolimus responsive to temperature type eyes are used in the preparation of body gel
Preparation technology:
Get tacrolimus and be dissolved in the small amount of ethanol solution, slowly join in the HP-aqueous solution while stir, continue to stir 2h, lyophilized overnight promptly gets.Tacrolimus hydroxypropyl-beta-cyclodextrin inclusion, sodium chloride, ethyl hydroxybenzoate and the hydroxypropyl emthylcellulose (E50) of recipe quantity are dissolved in the injection water, are placed in 2～8 ℃ of refrigerators, until the solution that obtains clear; The PEG-PLGA that slowly adds accurate weighing while stirring continues stirring and makes the PEG-PLGA grain all by water-wet, puts it into then and preserves more than the 24h in 2～8 ℃ of refrigerators; Until obtaining clarification, no agglomerate, finely dispersed solution, using the 0.1mol/L sodium hydroxide to regulate pH is 8, filters with 220 mesh sieve cloth then; Moisturizing is to total amount again; Pressure sterilizing, packing promptly gets.
Embodiment 3 tacrolimus pH responsive type eyes are used in the preparation of body gel
| Tacrolimus | 0.05g |
| Polyethylene glycol 6000 | 20.0g |
| Carbomer (NF940) | 2.0g |
| Methylcellulose | 0.8g |
| Glycerol | 0.8g |
| Methyl hydroxybenzoate | 0.03g |
| Propylparaben | 0.03g |
| Using the 0.1mol/L triethanolamine to regulate pH is 4 | |
| Add water to full dose | 100g |
Preparation technology:
Getting tacrolimus is dissolved in the small amount of ethanol solution; After treating that polyethylene glycol 6000 is heated to fusion in 60～70 ℃ of water-baths; Mixing, vigorous stirring also is poured over fused mass and forms thin layer on the corrosion resistant plate, makes it to be cooled to rapidly solid; Again this solid is positioned over 24h in 25～40 ℃ of vacuum drying ovens, promptly gets.The carbomer and the methylcellulose of accurate weighing are constantly added in an amount of injection water under the stirring; Continuing to stir makes the two granule all wetted; Placement is until the solution of being clarified, do not have agglomerate; Slowly add tacrolimus solid dispersion, glycerol, methyl hydroxybenzoate, the propylparaben for preparing while stirring, continue to stir until obtaining clarification, no agglomerate, finely dispersed solution; Regulate pH4 with the pH regulator agent, then with the filtration of 220 mesh sieve cloth, moisturizing is to total amount again, pressure sterilizing, and packing promptly gets.
Embodiment 4 tacrolimus pH responsive type eyes are used in the preparation of body gel
| Tacrolimus | 0.05g |
| Polyvinylpyrrolidone K30 | 30.0g |
| The cellulose acetate phthalate ester | 0.3g |
| Glucose | 0.8g |
| Methyl hydroxybenzoate | 0.03g |
| Propylparaben | 0.03g |
| Using the 0.1mol/L sodium hydroxide to regulate pH is 6 | |
| Add water to full dose | 100g |
Preparation technology:
Getting tacrolimus is dissolved in the small amount of ethanol solution; After treating that polyvinylpyrrolidone K30 is heated to fusion in 60～70 ℃ of water-baths; Mixing, vigorous stirring also is poured over fused mass and forms thin layer on the corrosion resistant plate, makes it to be cooled to rapidly solid; Again this solid is positioned over 24h in 25～40 ℃ of vacuum drying ovens, promptly gets.The cellulose acetate phthalate ester of accurate weighing is constantly added in an amount of injection water under the stirring; Continuing to stir makes its granule all wetted; Placement is until the solution of being clarified, do not have agglomerate; Slowly add tacrolimus solid dispersion, glucose, methyl hydroxybenzoate, the propylparaben for preparing while stirring, continue to stir until obtaining clarification, no agglomerate, finely dispersed solution; Regulate pH4 with the pH regulator agent, then with the filtration of 220 mesh sieve cloth, moisturizing is to total amount again, pressure sterilizing, and packing promptly gets.
Embodiment 5 tacrolimus ion-sensitive type eyes are used in the preparation of body gel
| Tacrolimus | 0.05g |
| Go acetyl-removed gellan gum | 0.6g |
| Sodium chloride | 0.8g |
| Benzalkonium chloride | 0.03g |
| Using the 0.1mol/L sodium hydroxide to regulate pH is 8 | |
| Add water to full dose | 100g |
Preparation technology:
The acetyl-removed gellan gum of going of accurate weighing is constantly added in an amount of injection water under the stirring, and continuation is stirred and is made it wetted, and placement is until the solution of being clarified, do not have agglomerate; The tacrolimus of recipe quantity is ground into impalpable powder, crosses 220 mesh sieves, gradation is ground in the substrate; Stir, slowly add benzalkonium chloride, sodium chloride while stirring, continue to stir until obtaining clarification, no agglomerate, finely dispersed solution; Regulate pH 8 with the 0.1mol/L sodium hydroxide, filter with 220 mesh sieve cloth then, moisturizing is to total amount again; Pressure sterilizing, packing promptly gets.
Embodiment 6 tacrolimus responsive to temperatures and ion-sensitive mixed type eye are used in the preparation of body gel
| Tacrolimus | 0.05g |
| Single succinyl-DM- | 1.5g |
| Poloxamer 407 (P407) | 14.0g |
| Sodium alginate | 0.1g |
| Sodium chloride | 0.8g |
| Benzalkonium chloride | 0.02g |
| Using the 0.1mol/L sodium hydroxide to regulate pH is 8 | |
| Add water to full dose | 100g |
Preparation technology:
Get tacrolimus and be dissolved in the small amount of ethanol solution, slowly join in single succinyl-DM-aqueous solution while stir, continue to stir 2h, lyophilized overnight promptly gets.The sodium alginate of accurate weighing is constantly added in an amount of injection water under the stirring, and continuation is stirred and is made its granule all wetted, and placement is until the solution of being clarified, do not have agglomerate; In addition the poloxamer 407 of accurate weighing is constantly stirred down and add in an amount of injection water, put it in 2～8 ℃ the refrigerator and preserve more than the 24h, until obtaining clarification, no agglomerate, finely dispersed solution; With poloxamer 407 and sodium alginate soln mix homogeneously, slowly add tacrolimus cyclodextrin clathrate, benzalkonium chloride, the sodium chloride for preparing while stirring, continue to stir until obtaining clarification, no agglomerate, finely dispersed solution; Regulate pH8 with the 0.1mol/L sodium hydroxide; Filter with 220 mesh sieve cloth then, moisturizing is to total amount again, pressure sterilizing; Packing promptly gets.
The responsive mixed type eye of embodiment 6 tacrolimus responsive to temperatures and pH is used in the preparation of body gel
Preparation technology:
Getting tacrolimus is dissolved in the small amount of ethanol solution; After treating that Myrj 45 is heated to fusion in 60～70 ℃ of water-baths; Mixing, vigorous stirring also is poured over fused mass and forms thin layer on the corrosion resistant plate, makes it to be cooled to rapidly solid; Again this solid is positioned over 24h in 25～40 ℃ of vacuum drying ovens, promptly gets.The carbomer 1342P NF of accurate weighing is constantly added in an amount of injection water under the stirring, and continuation is stirred and is made its granule all wetted, and placement is until the solution of being clarified, do not have agglomerate; In addition the poloxamer 407 of accurate weighing is constantly stirred down with poloxamer 188 and add in an amount of injection water, put it in 2～8 ℃ the refrigerator and preserve more than the 24h, until obtaining clarification, no agglomerate, finely dispersed solution; With poloxamer 407, poloxamer 188 and carbomer 1342PNF solution mix homogeneously, slowly add tacrolimus solid dispersion, methyl hydroxybenzoate, the sodium chloride for preparing while stirring, continue to stir until obtaining clarification, no agglomerate, finely dispersed solution; Regulate pH6 with the 0.1mol/L sodium hydroxide; Filter with 220 mesh sieve cloth then, moisturizing is to total amount again, pressure sterilizing; Packing promptly gets.
The inherent body gel of tacrolimus ophthalmic suppresses the pharmacodynamic experiment of rabbit cornea graft-rejection:
The present invention has set up rabbit allogeneic penetrating keratoplasty animal model, tacrolimus ophthalmic is used in the body gel is applied topically in the rabbit cornea transplantation model, inquires into the inhibitory action of its corneal post-transplantation immunological rejection.This experimental selection ciclosporin eye drop is observed the curative effect that tacrolimus ophthalmic is used in the body gel as positive control drug.
Experimental program is following:
(1) foundation of penetrating keratoplasty model: 10min auricular vein injection air is put to death donor rabbits before the art, drills through with diameter 6.25mm trepan to supply the eye central cornea to plant sheet, puts in a small amount of 1% hyaluronate sodium subsequent use.It is the art eye that all recipient rabbits are all selected right eye, and 3d art eye drips and uses the levofloxacin eye drop, every day 4 times before the operation.Slit lamp examination before the art, solving skill eye situation.Recipient rabbits intramuscular injection chlore-ammonia ketone (50mgkg
-1) and stable (2.5mgkg
-1) mixed liquor anaesthetize sb. generally.15min starting point PILO eye drop and 1% tetracain hydrochloride eye drop are each 3 times before the Rhizoma Atractylodis Macrocephalae, at interval 5min.The routine disinfection drape, the sterile working.Under operating microscope, get 6.25mm cornea central authorities holostrome and plant sheet and implant 6.0mm cornea central authorities penetrance plant bed immediately, drip 2 heparin sodium injections, with 10-0 import nylon wire interrupted suture 16 pins, toe-in does not bury.Art finishes injects a small amount of viscoelastic agent (1% hyaluronate sodium) in the anterior chamber, form the anterior chamber.Subconjunctival injection dexamethasone sodium phosphate injection and atropine sulfate injection drip the levofloxacin eye drop, and margo palpebrae is sewed up.Postoperative 1d removes the margo palpebrae suture, postoperative 3d local conventional levofloxacin eye drop every day 4 times used, 1% atropine eye drop and Tropicamide and Phenylephrine eye drop, every day 2 times.Behind the 3d according to the different eye drops of packet applications.
(2) experimental animal divides into groups and administration: corneal transplantation postoperative the 3rd day, and get rid of because the operation factor causes infection, hyphema, obliteratio camerae anterior or postoperative generation iris incarceration, hyphema and lenticular opacity eye, and in time replenish animal.Be divided into 4 groups at random, 8 every group, A group: normal saline group (negative control group); B group: ciclosporin eye drop group; C group: tacrolimus Oleum Ricini eye drop group; D group: the responsive gel for eye use group of tacrolimus body temperature.Each group is used the eye drop eye drip all from postoperative beginning in the 3rd day, and every day 3 times, each 100 μ l take place until rejection.
(3) observational technique and index: postoperative rose on the 1st, under slit lamp, observed the situation of corneal graft every day, and muddiness, edema and three indexs of new vessels are marked, and standards of grading are seen table 2.Three item rating sums be the same day rejection index (rejection index, RI).When RI >=6, be regarded as immunological rejection and take place, the record corneal graft time-to-live.
Table 2 corneal transplantation postoperative rejection standards of grading
(4) statistical procedures: adopt the SPSS14.0 of statistical software to carry out statistical analysis; Use one factor analysis of variance (One-WayANOVA) the relatively difference of the difference of each observation index, RI and the difference of respectively organizing corneal graft survival natural law between each group, P＜0.05 is for there being statistical significance.
The result:
The scoring of each group rabbit cornea post-transplantation being planted sheet muddiness, edema, new vessels in 10 days compares.Find from table 3 analysis of statistical data:
1. each group of corneal transplantation postoperative 10 days is planted the sheet muddiness and is had significant difference (F=7.694; P=0.001), plant the sheet edema have significant difference (F=4.667, P=0.009); Plant sheet new vessels not statistically significant (F=0.569; P=0.640), the RI value have significant difference (F=12.242, P=0.000).
2. with the normal saline matched group relatively, each medication group plant the sheet muddiness all obviously alleviate (P=0.000, P=0.05, P=0.001).Compare difference not statistically significant (P＞0.05) between each medication group.
3. with the normal saline matched group relatively, each medication group plant the sheet edema all obviously alleviate (P=0.020, P=0.02, P=0.006).Compare difference not statistically significant (P＞0.05) between each medication group.
4. with the normal saline matched group relatively, each medication group RI value all obviously reduce (P=0.000, P=0.000, P=0.000).Compare difference not statistically significant (P＞0.05) between each medication group.
The scoring that table 3 corneal transplantation postoperative was planted sheet muddiness, edema, new vessels in 10 days is (x ± s) relatively
| Divide into groups | Plant the sheet muddiness | Plant the sheet edema | Plant the sheet new vessels | RI |
| Negative control group | 2.62±0.74 | 1.88±0.64 | 1.38±0.52 | 5.88±1.12 |
| Ciclosporin eye drop group | 1.38±0.52** | 1.25±0.46** | 1.12±0.64 | 3.75±0.46** |
| Tacrolimus Oleum Ricini eye drop group | 1.50±0.53** | 1.00±0.53** | 1.25±0.71 | 4.00±0.76** |
| The responsive gel for eye use group of tacrolimus body temperature | 1.81±0.74** | 1.12±0.35** | 1.50±0.53 | 4.12±0.64** |
Compare * * P＜0.01 with normal saline group identical parameters
Each group rabbit cornea is planted the sheet time-to-live to be compared.The laboratory observation time is 100d.Data statistic analysis is found from table 4, and each is organized the corneal graft life span and compares with the normal saline group, all has significant difference (P＜0.01).Wherein normal saline group corneal graft life span is the shortest, and other respectively organize corneal graft life span not statistically significant.The result shows that the responsive gel for eye use of 0.05% tacrolimus body temperature can significantly suppress the immunological rejection that rabbit cornea is transplanted, with listing ciclosporin eye drop curative effect zero difference.
Table 4 is respectively organized rabbit cornea and is planted the sheet time-to-live
| Group | The corneal graft time-to-live (d) |  |
| Negative control group | 12、9、8、13、10、11、11、13 | 10.88±1.81 |
| Ciclosporin eye drop group | 100、100、100、100、100、100、100、100 | 100±0** |
| Tacrolimus Oleum Ricini eye drop group | 100、100、100、100、100、100、100、100 | 100±0** |
| The responsive gel for eye use group of tacrolimus body temperature | 100、100、100、100、100、100、100、100 | 100±0** |
Annotate: * * compares with the normal saline group, P＜0.01
Claims (3)
1. a tacrolimus ophthalmic is used in the body gel; It is characterized in that: medicine tacrolimus and adjuvant are prepared into the tacrolimus intermediate of high-dissolvability, in the tacrolimus intermediate for preparing, add ophthalmic gel base and other adjuvants and process tacrolimus ophthalmic and be used in the body gel;
It is the tacrolimus clathrate of carrier that said tacrolimus ophthalmic is used in that the body gel contains with the cyclodextrin derivative, according to mass fraction: 1 part of tacrolimus; 5～600 parts of cyclodextrin derivative; Said cyclodextrin derivative is one or more the mixture in beta-schardinger dextrin-, methyl-beta-schardinger dextrin-, HP-, dihydroxypropyl-beta-schardinger dextrin-, glucose-beta-schardinger dextrin-, single succinyl-DM-, maleoyl-dimethyl-beta cyclodextrin, carboxymethyl cyclodextrin or the sulfoalkyl cyclodextrin.
2. a tacrolimus ophthalmic as claimed in claim 1 is used in the method for preparing of body gel; It is characterized in that: adopt cyclodextrin inclusion technique to prepare the tacrolimus intermediate of high-dissolvability earlier, adding responsive to temperature type gel-type vehicle and other adjuvants are processed tacrolimus responsive to temperature type eye and are used in the body gel in the tacrolimus intermediate for preparing; Perhaps adopt pH responsive type gel-type vehicle to be prepared into tacrolimus pH responsive type eye and be used in the body gel; Perhaps adopt the ion-sensitive type gel-type vehicle to be prepared into tacrolimus ion-sensitive type eye and be used in the body gel; Perhaps adopt two kinds of machine-processed gel-type vehicles of different gellings to be prepared into tacrolimus mixed type eye and be used in the body gel.
3. be used in the method for preparing of body gel according to the tacrolimus ophthalmic described in the claim 2, it is characterized in that:
Said preparation temperature responsive type eye is used in the body gel preparation:
(1) the first tacrolimus intermediate of preparation high-dissolvability: the raw material of said preparation tacrolimus intermediate comprises: according to mass fraction: 1 part of tacrolimus; 5～600 parts of cyclodextrin derivative; The preparation of employing cyclodextrin inclusion technique; Described cyclodextrin inclusion technique is paddling process, microwave method or supercritical ultrasonics technology: tacrolimus and cyclodextrin derivative are dissolved in adequate amount of ethanol; Sonic oscillation 5～60min; Rotary Evaporators is 20～60 ℃ of solvent evaporated, and boulton process or freeze-drying are prepared into the tacrolimus intermediate of high-dissolvability;
(2) be dissolved in the injection water at the tacrolimus intermediate, antiseptic, isoosmotic adjusting agent, the viscosifier that prepare; Be placed in 2～8 ℃ of refrigerators; Until the solution that obtains clear, slowly add the responsive to temperature type gel-type vehicle of accurate weighing while stirring, continue stirring and make responsive to temperature type gel-type vehicle granule all by water-wet; Put it into then and preserve more than the 24h, in 2～8 ℃ the refrigerator until obtaining clarification, no agglomerate, finely dispersed solution; Regulate pH5～9 with the pH regulator agent, then with the filtration of 220 mesh sieve cloth, moisturizing is to total amount again, pressure sterilizing, and packing promptly gets;
Above raw material is according to mass fraction: 1 part of tacrolimus; 5～600 parts of cyclodextrin derivative; 0～6 part of antiseptic; 2～200 parts of isoosmotic adjusting agent; 0～1000 part of viscosifier; 2～1000 parts of responsive to temperature type gel-type vehicles; Said pH regulator agent is to adopt sodium hydroxide, or one or more the mixture in hydrochloric acid, citric acid, sodium citrate, glacial acetic acid, boric acid, triethanol ammonium or the phosphate buffer; Said antiseptic is one or more the mixture in chlorobutanol, thimerosal, benzalkonium chloride, benzalkonium bromide, methyl hydroxybenzoate, ethyl hydroxybenzoate or the propylparaben; Said isoosmotic adjusting agent is one or more the mixture in sodium chloride, glucose, mannitol, glycerol, sorbitol or the propylene glycol; Said viscosifier are one or more the mixture in hydroxypropyl emthylcellulose, methylcellulose, polyvidone or the polyvinyl alcohol; Said responsive to temperature type gel-type vehicle is poloxamer, polyethylene glycol-lactic acid block copolymer (PEG-PLGA (PLA)-PEG), ethylhydroxyethylcellulose or gather one or more the mixture in (N-isopropyl) acrylic acid amides;
Said preparation pH responsive type eye is used in the body gel preparation:
(1) the first tacrolimus intermediate of preparation high-dissolvability: the raw material of said preparation tacrolimus intermediate comprises: according to mass fraction: 1 part of tacrolimus; 5～600 parts of cyclodextrin derivative; The preparation of employing cyclodextrin inclusion technique; Described cyclodextrin inclusion technique is paddling process, microwave method or supercritical ultrasonics technology: tacrolimus and cyclodextrin derivative are dissolved in adequate amount of ethanol; Sonic oscillation 5～60min; Rotary Evaporators is 20～60 ℃ of solvent evaporated, and boulton process or freeze-drying are prepared into the tacrolimus intermediate of high-dissolvability;
(2) pH responsive type gel-type vehicle and the viscosifier with accurate weighing constantly add in an amount of injection water under the stirring; Continuing to stir makes the two granule all wetted; Placement is until the solution of being clarified, do not have agglomerate; Slowly add tacrolimus intermediate, antiseptic, the isoosmotic adjusting agent for preparing while stirring, continue to stir until obtaining clarification, no agglomerate, finely dispersed solution; Regulate pH2.5～4 with the pH regulator agent, then with the filtration of 220 mesh sieve cloth, moisturizing is to total amount again, pressure sterilizing, and packing promptly gets;
Above raw material is according to mass fraction: 1 part of tacrolimus; 5～600 parts of water-solubility carrier materials; 0～6 part of antiseptic; 2～200 parts of isoosmotic adjusting agent; 0～1000 part of viscosifier; 2～1000 parts of pH responsive type gel-type vehicles; Said pH regulator agent is to adopt sodium hydroxide, or one or more the mixture in hydrochloric acid, citric acid, sodium citrate, glacial acetic acid, boric acid, triethanol ammonium or the phosphate buffer; Said antiseptic is one or more the mixture in chlorobutanol, thimerosal, benzalkonium chloride, benzalkonium bromide, methyl hydroxybenzoate, ethyl hydroxybenzoate or the propylparaben; Said isoosmotic adjusting agent is one or more the mixture in sodium chloride, glucose, mannitol, glycerol, sorbitol or the propylene glycol; Said viscosifier are one or more the mixture in hydroxypropyl emthylcellulose, methylcellulose, polyvidone or the polyvinyl alcohol; Said pH responsive type gel-type vehicle is one or more the mixture among carbomer, cross-linked acrylic acid and derivant thereof, chitosan and derivant thereof, cellulose acetate-phthalate, cellulose acetate phthalate ester (CAP) or the Lacte;
Said preparation ion-sensitive type eye is used in the body gel preparation:
(1) the first tacrolimus intermediate of preparation high-dissolvability: the raw material of said preparation tacrolimus intermediate comprises: according to mass fraction: 1 part of tacrolimus; 5～600 parts of cyclodextrin derivative; The preparation of employing cyclodextrin inclusion technique; Described cyclodextrin inclusion technique is paddling process, microwave method or supercritical ultrasonics technology: tacrolimus and cyclodextrin derivative are dissolved in adequate amount of ethanol; Sonic oscillation 5～60min; Rotary Evaporators is 20～60 ℃ of solvent evaporated, and boulton process or freeze-drying are prepared into the tacrolimus intermediate of high-dissolvability;
(2) ion-sensitive type gel-type vehicle and the viscosifier with accurate weighing constantly add in an amount of injection water under the stirring, continue to stir to make the two granule all wetted, and placement is until the solution of being clarified, do not have agglomerate; Slowly add tacrolimus intermediate, antiseptic, the isoosmotic adjusting agent for preparing while stirring; Continue to stir until obtaining clarification, no agglomerate, finely dispersed solution, regulate pH5～9, filter with 220 mesh sieve cloth then with the pH regulator agent; Moisturizing is to total amount again; Pressure sterilizing, packing promptly gets;
Above raw material is according to mass fraction: 1 part of tacrolimus; 5～600 parts of water-solubility carrier materials; 0～6 part of antiseptic; 2～200 parts of isoosmotic adjusting agent; 0～1000 part of viscosifier; 2～1000 parts of ion-sensitive type gel-type vehicles; Said pH regulator agent is to adopt sodium hydroxide, or one or more the mixture in hydrochloric acid, citric acid, sodium citrate, glacial acetic acid, boric acid, triethanol ammonium or the phosphate buffer; Said antiseptic is one or more the mixture in chlorobutanol, thimerosal, benzalkonium chloride, benzalkonium bromide, methyl hydroxybenzoate, ethyl hydroxybenzoate or the propylparaben; Said isoosmotic adjusting agent is one or more the mixture in sodium chloride, glucose, mannitol, glycerol, sorbitol or the propylene glycol; Said viscosifier are one or more the mixture in hydroxypropyl emthylcellulose, methylcellulose, polyvidone or the polyvinyl alcohol; Said ion-sensitive type gel-type vehicle is one or more the mixture in acetyl-removed gellan gum or alginate and the polysaccharide thereof;
Said preparation mixed type eye is used in body gel preparation one:
(1) the first tacrolimus intermediate of preparation high-dissolvability: the raw material of said preparation tacrolimus intermediate comprises: according to mass fraction: 1 part of tacrolimus; 5～600 parts of cyclodextrin derivative; The preparation of employing cyclodextrin inclusion technique; Described cyclodextrin inclusion technique is paddling process, microwave method or supercritical ultrasonics technology: tacrolimus and cyclodextrin derivative are dissolved in adequate amount of ethanol; Sonic oscillation 5～60min; Rotary Evaporators is 20～60 ℃ of solvent evaporated, and boulton process or freeze-drying are prepared into the tacrolimus intermediate of high-dissolvability;
(2) the pH responsive type gel-type vehicle with accurate weighing constantly adds in an amount of injection water under the stirring, continues to stir to make pH responsive type gel-type vehicle granule all wetted, and placement is until the solution of being clarified, do not have agglomerate; Responsive to temperature type gel-type vehicle with accurate weighing constantly adds in an amount of injection water under the stirring in addition, the responsive to temperature type gel-type vehicle is put into 2～8 ℃ refrigerator and is preserved more than the 24h, until obtaining clarification, no agglomerate, finely dispersed solution; With responsive to temperature type gel-type vehicle and pH responsive type gel-type vehicle mix homogeneously, slowly add tacrolimus intermediate, antiseptic, the isoosmotic adjusting agent for preparing while stirring, continue to stir until obtaining clarification, no agglomerate, finely dispersed solution; Regulate pH2.5～6 with the pH regulator agent; Filter with 220 mesh sieve cloth then, moisturizing is to total amount again, pressure sterilizing; Packing promptly gets;
Above raw material is according to mass fraction: 1 part of tacrolimus; 5～600 parts of water-solubility carrier materials; 0～6 part of antiseptic; 2～200 parts of isoosmotic adjusting agent; 2～1000 parts of ion-sensitive type gel-type vehicles; 2～1000 parts of responsive to temperature type gel-type vehicles; Said pH regulator agent is to adopt sodium hydroxide, or one or more the mixture in hydrochloric acid, citric acid, sodium citrate, glacial acetic acid, boric acid, triethanol ammonium or the phosphate buffer; Said antiseptic is one or more the mixture in chlorobutanol, thimerosal, benzalkonium chloride, benzalkonium bromide, methyl hydroxybenzoate, ethyl hydroxybenzoate or the propylparaben; Said isoosmotic adjusting agent is one or more the mixture in sodium chloride, glucose, mannitol, glycerol, sorbitol or the propylene glycol; Said pH responsive type gel-type vehicle is one or more the mixture among carbomer, cross-linked acrylic acid and derivant thereof, chitosan and derivant thereof, cellulose acetate-phthalate, cellulose acetate phthalate ester (CAP) or the Lacte; Said responsive to temperature type gel-type vehicle is poloxamer, polyethylene glycol-lactic acid block copolymer (PEG-PLGA (PLA)-PEG), ethylhydroxyethylcellulose or gather one or more the mixture in (N-isopropyl) acrylic acid amides;
Said preparation mixed type eye is used in body gel preparation two:
(1) the first tacrolimus intermediate of preparation high-dissolvability: the raw material of said preparation tacrolimus intermediate comprises: according to mass fraction: 1 part of tacrolimus; 5～600 parts of cyclodextrin derivative; The preparation of employing cyclodextrin inclusion technique; Described cyclodextrin inclusion technique is paddling process, microwave method or supercritical ultrasonics technology: tacrolimus and cyclodextrin derivative are dissolved in adequate amount of ethanol; Sonic oscillation 5～60min; Rotary Evaporators is 20～60 ℃ of solvent evaporated, and boulton process or freeze-drying are prepared into the tacrolimus intermediate of high-dissolvability;
(2) the ion-sensitive type gel-type vehicle with accurate weighing constantly adds in an amount of injection water under the stirring, continues to stir to make ion-sensitive type gel-type vehicle granule all wetted, and placement is until the solution of being clarified, do not have agglomerate; Responsive to temperature type gel-type vehicle with accurate weighing constantly adds in an amount of injection water under the stirring in addition, the responsive to temperature type gel-type vehicle is put into 2～8 ℃ refrigerator and is preserved more than the 24h, until obtaining clarification, no agglomerate, finely dispersed solution; With responsive to temperature type gel-type vehicle and ion-sensitive type gel-type vehicle mix homogeneously, slowly add tacrolimus intermediate, antiseptic, the isoosmotic adjusting agent for preparing while stirring, continue to stir until obtaining clarification, no agglomerate, finely dispersed solution; Regulate pH5～9 with the pH regulator agent; Filter with 220 mesh sieve cloth then, moisturizing is to total amount again, pressure sterilizing; Packing promptly gets;
Above raw material is according to mass fraction: 1 part of tacrolimus; 5～600 parts of water-solubility carrier materials; 0～6 part of antiseptic; 2～200 parts of isoosmotic adjusting agent; 2～1000 parts of ion-sensitive type gel-type vehicles; 2～1000 parts of responsive to temperature type gel-type vehicles; Said pH regulator agent is to adopt sodium hydroxide, or one or more the mixture in hydrochloric acid, citric acid, sodium citrate, glacial acetic acid, boric acid, triethanol ammonium or the phosphate buffer; Said antiseptic is one or more the mixture in chlorobutanol, thimerosal, benzalkonium chloride, benzalkonium bromide, methyl hydroxybenzoate, ethyl hydroxybenzoate or the propylparaben; Said isoosmotic adjusting agent is one or more the mixture in sodium chloride, glucose, mannitol, glycerol, sorbitol or the propylene glycol; Said ion-sensitive type gel-type vehicle is one or more the mixture in acetyl-removed gellan gum or alginate and the polysaccharide thereof; Said responsive to temperature type gel-type vehicle is poloxamer, polyethylene glycol-lactic acid block copolymer (PEG-PLGA (PLA)-PEG), ethylhydroxyethylcellulose or gather one or more the mixture in (N-isopropyl) acrylic acid amides.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009103077536A CN101810563B (en) | 2009-09-25 | 2009-09-25 | Tacrolimus ophthalmic in-situ gel preparation and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009103077536A CN101810563B (en) | 2009-09-25 | 2009-09-25 | Tacrolimus ophthalmic in-situ gel preparation and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101810563A CN101810563A (en) | 2010-08-25 |
| CN101810563B true CN101810563B (en) | 2012-04-25 |
Family
ID=42618027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009103077536A Expired - Fee Related CN101810563B (en) | 2009-09-25 | 2009-09-25 | Tacrolimus ophthalmic in-situ gel preparation and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101810563B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102120032B (en) * | 2010-12-29 | 2012-02-29 | 济南市皮肤病防治院 | Water-soluble substrate suitable for preparing water-soluble preparations of bleomycin and homologues thereof |
| CN102525877A (en) * | 2010-12-30 | 2012-07-04 | 国家人口计生委科学技术研究所 | Preparation of butoconazole nitrate in-situ gel |
| CN103142463B (en) * | 2013-03-05 | 2015-09-09 | 宁夏康亚药业有限公司 | Medical composite for eye, its preparation method and application |
| CN104971344B (en) * | 2015-07-14 | 2017-09-15 | 珠海亿胜生物制药有限公司 | Recombination human basic fibroblast growth factor instant gel preparation and preparation method thereof |
| CN108066745A (en) * | 2017-12-26 | 2018-05-25 | 兆科药业（广州）有限公司 | A kind for the treatment of process of Ciclosporin eye gel |
| US20210128534A1 (en) * | 2018-02-26 | 2021-05-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Drug delivery systems |
| CN112730015B (en) * | 2019-10-28 | 2022-11-22 | 上海云泽生物科技有限公司 | Dilution for stabilizing tacrolimus and application thereof |
| CN113577011B (en) * | 2021-07-22 | 2024-04-02 | 厦门大学 | Tacrolimus ophthalmic preparations and preparation methods and uses thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1241946A (en) * | 1996-12-25 | 2000-01-19 | 山之内制药株式会 | Immediately disintegrable medicinal compositions |
| CN101288643A (en) * | 2008-06-17 | 2008-10-22 | 杨喜鸿 | Gel composition containing tacrolimu and its preparation method and medicinal application |
-
2009
- 2009-09-25 CN CN2009103077536A patent/CN101810563B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1241946A (en) * | 1996-12-25 | 2000-01-19 | 山之内制药株式会 | Immediately disintegrable medicinal compositions |
| CN101288643A (en) * | 2008-06-17 | 2008-10-22 | 杨喜鸿 | Gel composition containing tacrolimu and its preparation method and medicinal application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101810563A (en) | 2010-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101810563B (en) | Tacrolimus ophthalmic in-situ gel preparation and preparation method thereof | |
| CN1198587C (en) | Tear-gland specific emulsion for local application to eye tissue | |
| DE60214697T2 (en) | DEVICE FOR RELEASING AN OPHTHALMIC MEDICINAL PRODUCT | |
| AU2015289387B2 (en) | Suspension compositions of cyclosporin A for subconjunctival and periocular injection | |
| CN1084079A (en) | Ophthalmic composition | |
| CN101137370A (en) | Liquid formulations for treatment of diseases or conditions | |
| CN109364019A (en) | A kind of eye-drops preparations and preparation method thereof for preventing and treating cataract | |
| CN101716214A (en) | Medical composition containing dandelion extract as well as novel application and preparation method thereof | |
| CN101653413B (en) | Tacrolimus ophthalmic emulsion and its preparation method | |
| WO2022074557A1 (en) | Drug containing dissolvable ocular inserts and method of using same | |
| CN100478025C (en) | A kind of cyclosporine A eye microemulsion preparation and preparation method thereof | |
| CN101537010A (en) | Eye drop preparation and its preparing method | |
| JPH0565221A (en) | Ophthalmic microsphere | |
| CN101284006A (en) | Medicine composition for treating eye disease | |
| CN100584332C (en) | Eye-drops preparations containing tetrandrine and its application for preparing medicine therewith | |
| CN100560055C (en) | Gel for eye use and preparation method thereof | |
| CN103977011A (en) | Travoprost and timolol-containing ophthalmic gel and preparation method thereof | |
| CN108186639B (en) | A kind of pharmaceutical composition of SS 717 | |
| CN104274406B (en) | A kind of injection tacrolimus fat emulsion and preparation method thereof | |
| WO2010141068A1 (en) | Opthalmic compositions of cyclosporin | |
| CN103990137A (en) | Slow-release agent of mucoadhesive polymer eye medicines | |
| CN101869547B (en) | Tacrolimus injection preparation | |
| CN104523575B (en) | A kind of hydrobenzole hydrochloride gel for eye and preparation method thereof | |
| CN114246935B (en) | Cyclosporin-containing composition and application thereof in preparation of dry eye treatment drugs | |
| Mundada | Update on Polymers for Ocular Drug Delivery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120425 Termination date: 20210925 |